知搜-全球专利检索

  1. 登录
  2. 注册

搜索结果

603 条记录 (耗时 0.032 秒)

    DERMAL DROPS
    61.
    发明申请
    DERMAL DROPS 失效

    公开(公告)号：US20080107677A1

    公开(公告)日：2008-05-08

    申请号：US11836375

    申请日：2007-08-09

    申请人： Bryan HIROMOTO

    发明人： Bryan HIROMOTO

    IPC分类号： A61K36/07 ,  A61P3/00 ,  A61P7/00 ,  A61P15/00 ,  A61P17/00 ,  A61P27/00 ,  A61P29/00 ,  C12N1/14

    CPC分类号： A61K36/07 ,  A61K9/0014

    摘要： Dermal drops that, when applied topically to animal subjects, can ameliorate symptoms of conditions such as diabetes and Parkinson's disease are prepared as concentrates of the culture filtrate of a Basidiomycete fungus grown under appropriate conditions. The concentrate can also be used as a convenient source of liquid compost factor.

    摘要翻译： 在局部应用于动物受试者的情况下，可以改善诸如糖尿病和帕金森病等病症的症状的真皮滴剂，其制备为在合适条件下生长的担子菌真菌的培养物滤液的浓缩物。 浓缩物也可用作液体堆肥因子的方便来源。

    Pharmacological vitreolysis
    62.
    发明申请
    Pharmacological vitreolysis 有权
    药理性玻璃体解

    公开(公告)号：US20080095753A1

    公开(公告)日：2008-04-24

    申请号：US11786354

    申请日：2007-04-11

    申请人： Steve Pakola ,  Marc De Smet

    发明人： Steve Pakola ,  Marc De Smet

    IPC分类号： A61K38/46 ,  A61P27/00

    CPC分类号： A61K38/484 ,  A61K45/06 ,  C12Y302/01023 ,  C12Y302/01035 ,  C12Y304/21007 ,  C12Y304/24007 ,  C12Y402/02004 ,  C12Y402/02005 ,  C12Y402/02019 ,  A61K2300/00

    摘要： Methods of treating or preventing a disorder, or a complication of a disorder, of an eye of a subject, comprising contacting a vitreous and/or aqueous humor with a composition comprising a truncated form of plasmin comprising a catalytic domain of plasmin (TPCD) are disclosed. TPCDs include, but are not limited to, miniplasmin, microplasmin and derivatives and variants thereof. The methods of the invention can be used to reduce the viscosity of the vitreous, liquefy the vitreous, induce posterior vitreous detachment, reduce hemorrhagic blood from the eye, clear or reduce materials toxic to the eye, clear or reduce intraocular foreign substances from the eye, increase diffusion of a composition administered to an eye, reduce extraretinal neovascularization and any combinations thereof. The method can be used in the absence of, or as an adjunct to, vitrectomy.

    摘要翻译： 包括使玻璃体和/或房水与包含纤溶酶（TPCD）的催化结构域的截短形式的纤溶酶的组合物接触的方法，所述方法包括使玻璃体和/或房室液体接触， 披露 TPCD包括但不限于微型血小板，微量血浆​​及其衍生物和变体。 本发明的方法可用于降低玻璃体粘度，液化玻璃体，诱导玻璃体后脱离，减少眼睛出血血液，清除或减少眼睛有毒的物质，清除或减少眼内异物 增加施用于眼睛的组合物的扩散，减少外耳道新生血管形成及其任何组合。 该方法可用于玻璃体切除术的缺失或辅助。

    Contact lens and eye drop rewetter compositions and methods
    68.
    发明申请
    Contact lens and eye drop rewetter compositions and methods 审中-公开
    隐形眼镜和滴眼液回流器组合物和方法

    公开(公告)号：US20050266089A1

    公开(公告)日：2005-12-01

    申请号：US11192718

    申请日：2005-07-29

    申请人： James Cook ,  Stanley Huth

    发明人： James Cook ,  Stanley Huth

    IPC分类号： A61K9/00 ,  A61K31/728 ,  A61K33/00 ,  A61K45/06 ,  A61P27/00 ,  A61P27/02 ,  A61K33/14

    CPC分类号： A61K9/0048 ,  A61K31/728 ,  A61K33/00 ,  A61K45/06 ,  A61K2300/00

    摘要： Stable ophthalmic formulations comprising hyaluronic acid (sodium hyaluronate) as the primary active demulcent ingredient, stabilized oxy-chloro complex (available commercially as OcuPure™ from Advanced Medical Optics, Purite® from Allergan, and Purogene from Biocide) for preservative efficacy, balanced salts mimicking the tear film, and sodium borate as a buffer are disclosed. In one embodiment, preferred stable formulations may be used in the human eye with or without contact lenses. In another embodiment preferred formulations may also be used as a storage and conditioning solution for contact lenses following disinfection.

    摘要翻译： 包含透明质酸（透明质酸钠）作为主要的活性缓和成分的稳定的眼用制剂，稳定的氯 - 氯络合物（可从Advanced Medical Optics，Allergan的Purite，以及来自Biocide的Purogene购得），用于防腐​​功效 公开了模仿泪膜的平衡盐和作为缓冲剂的硼酸钠。 在一个实施方案中，优选的稳定制剂可以在具有或不具有隐形眼镜的人眼中使用。 在另一个实施方案中，优选的制剂也可以用作消毒后的隐形眼镜的储存和调理溶液。